A Study of S6G5T-3 in the Treatment of Acne Vulgaris

Completed · Phase 3

Conditions studied: Acne Vulgaris

In brief

To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.

Key facts

Study ID

NCT03761784

Run by

Sol-Gel Technologies, Ltd.

People needed

424

Starts

2018-12-21

Expected to finish

2019-12-31

Last updated by the study team

2021-12-16

Who can join

Age: 9 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must sign an Institutional Review Board (IRB) approved written informed consent for this study.
• Male and female 9 years of age and older.
• Have 2 or fewer cysts or nodules.

You may not qualify if…

• More than 2 acne nodules or cysts (defined as an inflammatory lesion greater than or equal to 5 millimeter (mm) in diameter).
• Acne conglobata, acne fulminans, and secondary acne (for example, chloracne, drug-induced acne).
• History of blood dyscrasia (for example, leukemia, haemophilia, sickle cell anemia, multiple myeloma).
• Underlying disease that requires the use of interfering topical or systemic therapy.
• Other dermatological conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, atopic dermatitis, perioral dermatitis, or rosacea.

Where it is running

• Dermatology Consulting Services — High Point, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.